These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24689234)

  • 1. [Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism].
    Zhu SL; Zhang ZY; Ren GP; Ye XL; Ma L; Yu D; Han MM; Zhao JZ; Zhang TY; Li DS
    Yao Xue Xue Bao; 2013 Dec; 48(12):1778-84. PubMed ID: 24689234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy.
    Zhu S; Wu Y; Ye X; Ma L; Qi J; Yu D; Wei Y; Lin G; Ren G; Li D
    Mol Cell Biochem; 2016 Sep; 420(1-2):107-19. PubMed ID: 27435856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
    Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
    Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic effect of fibroblast growth factor 21 on hypertension induced by insulin resistance].
    Zhu SL; Ren GP; Zhang ZY; Wang WF; Ye XL; Han MM; Zhao JZ; Xu TY; Liu MY; Li DS
    Yao Xue Xue Bao; 2013 Sep; 48(9):1409-14. PubMed ID: 24358774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
    Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
    FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats.
    Wang WF; Li SM; Ren GP; Zheng W; Lu YJ; Yu YH; Xu WJ; Li TH; Zhou LH; Liu Y; Li DS
    Endocrine; 2015 May; 49(1):119-29. PubMed ID: 25306889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dietary monosodium glutamate on HFCS-induced hepatic steatosis: expression profiles in the liver and visceral fat.
    Collison KS; Maqbool ZM; Inglis AL; Makhoul NJ; Saleh SM; Bakheet RH; Al-Johi MA; Al-Rabiah RK; Zaidi MZ; Al-Mohanna FA
    Obesity (Silver Spring); 2010 Jun; 18(6):1122-34. PubMed ID: 20111022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
    Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
    Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
    Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
    J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
    Su X; Kong Y; Peng D
    Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factor 21 (FGF21) Administration Sex-Specifically Affects Blood Insulin Levels and Liver Steatosis in Obese
    Makarova E; Kazantseva A; Dubinina A; Denisova E; Jakovleva T; Balybina N; Bgatova N; Baranov K; Bazhan N
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
    Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
    Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
    Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
    Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
    Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term ingestion of monosodium L-glutamate did not induce obesity, dyslipidemia or insulin resistance: a two-generation study in mice.
    Nakamura H; Kawamata Y; Kuwahara T; Smriga M; Sakai R
    J Nutr Sci Vitaminol (Tokyo); 2013; 59(2):129-35. PubMed ID: 23727643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice.
    Yamazaki Y; Usui I; Kanatani Y; Matsuya Y; Tsuneyama K; Fujisaka S; Bukhari A; Suzuki H; Senda S; Imanishi S; Hirata K; Ishiki M; Hayashi R; Urakaze M; Nemoto H; Kobayashi M; Tobe K
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1179-86. PubMed ID: 19724016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.
    Gan L; Meng ZJ; Xiong RB; Guo JQ; Lu XC; Zheng ZW; Deng YP; Luo BD; Zou F; Li H
    Acta Pharmacol Sin; 2015 May; 36(5):597-605. PubMed ID: 25891086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study.
    Watanabe M; Risi R; Camajani E; Contini S; Persichetti A; Tuccinardi D; Ernesti I; Mariani S; Lubrano C; Genco A; Spera G; Gnessi L; Basciani S
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32708435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.